Personalized prognostic tools and gene-based therapies may improve the survival and quality of life of patients suffering from glioblastoma, an aggressive and deadly form of brain cancer.

Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that Jonathan H. Dinsmore Ph.D., Senior Vice President -- Regulatory and Clinical, has been invited to present to the U.S.